Stock Research: Day One Biopharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Day One Biopharmaceuticals

NSQ:DAWN US23954D1090
70
  • Value
    76
  • Growth
    96
  • Safety
    Safety
    66
  • Combined
    89
  • Sentiment
    7
  • 360° View
    360° View
    70
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 70 (better than 70% compared with alternatives), overall professional sentiment and financial characteristics for the stock Day One Biopharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Day One Biopharmaceuticals. The consolidated Value Rank has an attractive rank of 76, which means that the share price of Day One Biopharmaceuticals is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 76% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 96, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 66. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 7. Professional investors are more confident in 93% other stocks. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 n/a n/a n/a
Growth
96 n/a n/a n/a
Safety
Safety
66 n/a n/a n/a
Sentiment
7 n/a n/a n/a
360° View
360° View
70 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 n/a n/a n/a
Opinions Change
4 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
52 n/a n/a n/a
Sentiment
7 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 n/a n/a n/a
Growth
96 n/a n/a n/a
Safety Safety
66 n/a n/a n/a
Combined
89 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
58 n/a n/a n/a
Price vs. Earnings (P/E)
100 n/a n/a n/a
Price vs. Book (P/B)
28 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
76 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 n/a n/a n/a
Profit Growth
76 n/a n/a n/a
Capital Growth
88 n/a n/a n/a
Stock Returns
80 n/a n/a n/a
Growth
96 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
86 n/a n/a n/a
Refinancing
75 n/a n/a n/a
Liquidity
13 n/a n/a n/a
Safety Safety
66 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Day One Biopharmaceuticals and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock has excellent financial qualities (value, growth, and safety are high) but a negative professional market sentiment. It suits an investor who believes the negative sentiment is a temporary overreaction and is looking for a financially solid company.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: